<doc>
  <docmeta id="113s2141is">
    <bill congress="113" type="s" number="2141" version="is"/>
    <revision size="33676" annotations="0" status="complete" id="7" commit-time="2014-03-26T20:21:51Z" committer="mbohmer" doc="113s2141is/7.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-Senate" public-private="public">
  <metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 S2141 IS: Sunscreen Innovation Act</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. Senate</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-03-13</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code>
    <congress>113th CONGRESS</congress>
    <session>2d Session</session>
    <legis-num>S. 2141</legis-num>
    <current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
    <action>
      <action-date date="20140313">March 13, 2014</action-date>
      <action-desc>
        <sponsor name-id="S259">Mr. Reed</sponsor> (for himself and <cosponsor name-id="S305">Mr. Isakson</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name>
      </action-desc>
    </action>
    <legis-type>A BILL</legis-type>
    <official-title>To amend the Federal Food, Drug, and Cosmetic Act to provide an alternative process for
			 review of safety and effectiveness of nonprescription sunscreen active
			 ingredients and for other purposes. </official-title>
  </form>
  <legis-body>
    <section id="S1" section-type="section-one">
      <enum>1.</enum>
      <header>Short
			 title</header>
      <text display-inline="no-display-inline">This Act may be cited as
			 the <quote>
          <short-title>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sunscreen Innovation Act" proposed="true">Sunscreen Innovation
			 Act</cato:entity-ref>
          </short-title>
        </quote>.</text>
    </section>
    <section id="id2657d9a11c6d44dcafa545cc09b3192e">
      <enum>2.</enum>
      <header>Regulation of
			 nonprescription sunscreen active ingredients</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V/sch:A">Subchapter A of chapter V</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/351/et    -seq">21 U.S.C. 351 et
			 seq</cato:entity-ref>.)</cato:entity> is amended by adding at the end the following:</text>
      <quoted-block display-inline="no-display-inline" id="id5F583987F3AF41AFA88E640167C2B510" style="OLC">
        <section id="id09E5D37489EC4D84A278A032DBA7F932">
          <enum>524B.</enum>
          <header>Procedures
				for classifying sunscreen active ingredients</header>
          <subsection commented="no" id="id32E4E2EFAED14A7AAC64B0F202539F26">
            <enum>(a)</enum>
            <header>In general</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall review and determine whether nonprescription sunscreen
			 conditions are
				generally recognized as safe and effective and shall ensure that
			 any such
			 conditions that
				are marketed in the United States are appropriately labeled.</text>
          </subsection>
          <subsection id="idA93947450E6F434F85AC2E1E23851A37">
            <enum>(b)</enum>
            <header>Definitions</header>
            <paragraph id="idbb0dd6f7fe0f4a6b87a99e3379f0c6fe">
              <enum>(1)</enum>
              <header>Active
				ingredient</header>
              <text>The term <term>active ingredient</term> means any
				component that is intended to furnish pharmacological activity or
			 other direct
				effect in the diagnosis, cure, mitigation, treatment, or prevention
			 of disease,
				or to affect the structure or function of the body of humans or
			 animals.
				The term includes components that may undergo chemical change in
			 the
				manufacture of a drug and may be present in a drug in a
			 modified form
				intended to furnish the specified activity or effect.</text>
            </paragraph>
            <paragraph id="id9629e772152d43fa9dc1276a8d726694">
              <enum>(2)</enum>
              <header>Sunscreen
				active ingredient</header>
              <text>The term <term>sunscreen active
				ingredient</term> means an active ingredient that absorbs, reflects, or
				scatters radiation in the ultraviolet range at wavelengths from 290
			 to 400
				nanometers.</text>
            </paragraph>
            <paragraph id="id8561239ab2cb45fd834a2a95f51d75d6">
              <enum>(3)</enum>
              <header>Sunscreen
				condition</header>
              <text>The term <term>sunscreen condition</term> means a sunscreen active ingredient (or a combination of sunscreen active ingredients), dosage
			 form, dosage strength, or route of administration, marketed for a specific
			 nonprescription use.</text>
            </paragraph>
          </subsection>
          <subsection commented="no" id="id008fa93ba90749c49b80c64ebbd3f0b1">
            <enum>(c)</enum>
            <header>Criteria for
				eligibility</header>
            <text>To be eligible for review under this section, a sunscreen condition shall—</text>
            <paragraph commented="no" id="id288B75FD386948B3A45199BC461DF7A8">
              <enum>(1)</enum>
              <text>not be included in the stayed sunscreen
			 monograph; and</text>
            </paragraph>
            <paragraph commented="no" id="id8EBF62253C81420A94AE9663F843E36E">
              <enum>(2)</enum>
              <text>have been marketed as a  nonprescription sunscreen condition in the United States or at least 1
			 other country, or marketed as a cosmetic or dietary supplement in 1 or
			 more counties other than the United States—</text>
              <subparagraph commented="no" id="idD57880AC2D144B8BAC3BD30085F11D4D">
                <enum>(A)</enum>
                <text>for a minimum of 5 continuous years; and</text>
              </subparagraph>
              <subparagraph commented="no" id="id475D4875468B4338920DFBFB07FD6EA0">
                <enum>(B)</enum>
                <text>in sufficient quantity, as determined by the Secretary based upon the information submitted under
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:1/sp:D" proposed="true">subparagraphs (D)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:1/sp:E" proposed="true">(E) of subsection (d)(1)</cato:entity-ref> and, if
			 applicable, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:2/sp:A/cl:ii" proposed="true">subsection (d)(2)(A)(ii)</cato:entity-ref>.</text>
              </subparagraph>
            </paragraph>
          </subsection>
          <subsection id="id18e25fa5485441e5be10d04e180d4865">
            <enum>(d)</enum>
            <header>Application for eligibility</header>
            <paragraph id="idE1C65F76DFF84F479BC736A8EC056FD3">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>A sponsor of a nonprescription sunscreen condition
				described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:c" proposed="true">subsection (c)</cato:entity-ref> desiring to market such condition in
			 the United
				States may submit an application to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, in such manner
			 and
				containing such information as required by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, including
			 the
				following:</text>
              <subparagraph id="idc5a86345742f479ca86d3619d29d5883">
                <enum>(A)</enum>
                <text>Basic information
				about the sunscreen condition (including a description of each
			 active
				ingredient, pharmacologic class, intended nonprescription use,
			 nonprescription
				strength and dosage form, route of administration, and directions
			 for
				use).</text>
              </subparagraph>
              <subparagraph id="idB3B88ED18E7E4087945530AF0E7FE45D">
                <enum>(B)</enum>
                <text>A detailed chemical description of the sunscreen active ingredient that includes a full description
			 of the drug substance, including its physical and chemical
			 characteristics, the method of synthesis (or isolation) and purification
			 of the drug substance, and any specifications and analytical methods
			 necessary to ensure the identity, strength, quality, and purity of the
			 drug substance, including reference to the current edition of the official
			 National Formulary, the United States Pharmacopeia, or foreign
			 compendiums, where applicable.</text>
              </subparagraph>
              <subparagraph id="idFDA28802F6CE48169B68729D97DE7788">
                <enum>(C)</enum>
                <text>A list of each
				country in which the sunscreen condition has been marketed.</text>
              </subparagraph>
              <subparagraph id="idE04D9F0B12114819949DE356BD1098CB">
                <enum>(D)</enum>
                <text>The cumulative
				total number of dosage units sold for each dosage form of the
			 sunscreen
				condition, including total weight of the active ingredient, package
			 size for
				each dosage form in which the condition is marketed as
			 nonprescription, and an
				estimate of the minimum number of potential consumer exposures to
			 the
				condition.</text>
              </subparagraph>
              <subparagraph id="idE6804C8AF2D844EBA4D2BBFED21EC261">
                <enum>(E)</enum>
                <text>The use pattern
				(according to the label) for each country in which the sunscreen
			 condition is
				marketed and any changes in use pattern that have occurred over
			 time.</text>
              </subparagraph>
              <subparagraph id="id8c39d2b897f8434682f6790f81c21685">
                <enum>(F)</enum>
                <text>A list of all
				countries in which the sunscreen condition has been withdrawn from
			 marketing or
				in which an application for nonprescription marketing approval has
			 been denied
				and an explanation for such withdrawal or application denial.</text>
              </subparagraph>
            </paragraph>
            <paragraph commented="no" id="iddbf8aaf6a9554fd7a4ff98ee7e7445bf">
              <enum>(2)</enum>
              <header>Sunscreen conditions that have not been marketed in the United States for 5 continuous years</header>
              <subparagraph commented="no" id="id7E9940EF6C484F1BB4D4A1686F6D521D">
                <enum>(A)</enum>
                <header>In general</header>
                <text>In the case of an application with respect to a nonprescription sunscreen condition that has not
			 been marketed in the United States for 5 continuous years, in addition to
			 the information required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:1" proposed="true">paragraph
			 (1)</cato:entity-ref>, the sponsor shall submit the following information for each
				country in which the sunscreen condition has been marketed:</text>
                <clause id="id7153F824D631477A91F95602857D8354">
                  <enum>(i)</enum>
                  <text>The manner in
				which the sunscreen condition has been marketed to consumers. If
			 the sunscreen
				condition is marketed to consumers as a nonprescription pharmacy
			 only
				condition, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may require supplemental information.</text>
                </clause>
                <clause commented="no" id="id199F176CAB4F4E0083A97C5465E7B271">
                  <enum>(ii)</enum>
                  <text>A description of the population demographics and the source from which this information has been
			 compiled, to ensure that the sunscreen condition's use can be reasonably
			 extrapolated to the population of the United States.</text>
                </clause>
                <clause id="id924AD15457324C939B9524673D958FB8">
                  <enum>(iii)</enum>
                  <text>A description of
				the country’s system for identifying adverse drug experiences,
			 especially those
				found in nonprescription marketing experience, including method of
			 collection
				if applicable.</text>
                </clause>
                <clause id="id7926B88CB2FF4722804A49861A3E1398">
                  <enum>(iv)</enum>
                  <text>A statement of how long the sunscreen condition has been marketed in each country and how long the
			 current product labeling has been in use, accompanied by a copy of the
			 current product labeling, including a translation into English of any
			 labeling that is not in English, and a statement of whether the current
			 product labeling has been authorized, accepted, or approved by a
			 regulatory body in
			 each country where the condition is marketed.</text>
                </clause>
                <clause id="idDD9CBBFA1BBF4EC9B20D46671242E4B8">
                  <enum>(v)</enum>
                  <text>A list of all
				countries where the sunscreen condition is marketed as a
			 prescription drug only
				and an explanation for such restriction.</text>
                </clause>
              </subparagraph>
              <subparagraph id="id1E7DBBAF279D443BA83EFA5BB855722A">
                <enum>(B)</enum>
                <header>Sunscreen conditions that have been marketed in more than 5 countries</header>
                <clause id="id2BD00871B62245DBA950594D3343E3D7">
                  <enum>(i)</enum>
                  <header>In general</header>
                  <text>In the case of a sunscreen condition that has been marketed as a nonprescription sunscreen in more
			 than 5 countries, with a
			 minimum of 5 continuous years of marketing in at least one such country,
			 the
			 sponsor—</text>
                  <subclause id="id25DF5101CF2F461A9D0B82EB70CFB34B">
                    <enum>(I)</enum>
                    <text>may submit information in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:2/sp:A/cl:i..iv" proposed="true">clauses (i) through (iv) of
			 subparagraph (A)</cato:entity-ref> with respect to only 5 such countries, including—</text>
                    <item id="id882E69A83AB74FC99657581E1C87A390">
                      <enum>(aa)</enum>
                      <text>the country with a
			 minimum
			 of 5 continuous years of nonprescription marketing;</text>
                    </item>
                    <item id="id0464FAD816BC4E23BE7CB1157BB2BE1F">
                      <enum>(bb)</enum>
                      <text>the country with 
			 the longest duration of marketing; and</text>
                    </item>
                    <item id="id86F9A2F2BD05409F875AE30106BB0686">
                      <enum>(cc)</enum>
                      <text>the country with the most support
			 for marketing, such as a large volume of sales with cultural
			 diversity among users of the product; and</text>
                    </item>
                  </subclause>
                  <subclause id="id7E07931F6C504836B20908F657B3CAFB">
                    <enum>(II)</enum>
                    <text>shall explain the basis for the countries selected under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:2/sp:B/cl:i/scl:I" proposed="true">subclause (I)</cato:entity-ref>; and</text>
                  </subclause>
                  <subclause id="id1D20F7645EFC4EBCAA80AF0DD1A57F0B">
                    <enum>(III)</enum>
                    <text>shall provide information from more than 5
			 countries if such information is needed to support the application.</text>
                  </subclause>
                </clause>
                <clause id="idC3054B5C4A4744479F81962DA37A0DC5">
                  <enum>(ii)</enum>
                  <header>Requirement</header>
                  <text>If the sunscreen condition
			 meets the criteria under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:2/sp:B/cl:i/scl:I/i:aa..cc" proposed="true">items (aa) through (cc) of clause (i)(I)</cato:entity-ref> in 1 or
			 more countries listed in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:802/ss:b/p:1/sp:A">section 802(b)(1)(A)</cato:entity-ref>, at least 1 such country
			 shall be included among the 5 countries selected under such <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:2/sp:B/cl:i/scl:I" proposed="true">clause (i)(I)</cato:entity-ref>.</text>
                </clause>
              </subparagraph>
            </paragraph>
            <paragraph commented="no" id="id835519D888CC4BD3868F1B5041AE175B">
              <enum>(3)</enum>
              <header>Pending
				applications</header>
              <text>The requirements of this subsection shall not apply
				to a sunscreen condition deemed eligible for review of safety and
			 effectiveness
				by publication of a notice of eligibility in the Federal Register
			 prior to the
				date of enactment of the <short-title>
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sunscreen Innovation Act" proposed="true">Sunscreen Innovation
				Act</cato:entity-ref>
                </short-title>. Applications for such sunscreen conditions shall be
				considered in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:g" proposed="true">subsection (g)</cato:entity-ref>.</text>
            </paragraph>
          </subsection>
          <subsection commented="no" id="id8c792c63bc7d44a6ac81335da7d53470">
            <enum>(e)</enum>
            <header>Public
				availability</header>
            <text>If a condition is found eligible under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d" proposed="true">subsection
				(d)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make the application publicly available,
			 with
				redactions for confidential commercial information or trade secret
			 information,
				and any other information exempt from disclosure pursuant to
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18/1905">section 1905 of
				title 18, United States Code</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/552/b">
                <external-xref legal-doc="usc" parsable-cite="usc/5/552">section 552(b)</external-xref> of title 5, United
			 States Code</cato:entity-ref>, or
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:j">section 301(j)</cato:entity-ref> of this Act. Applications shall remain confidential
			 during the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary's</cato:entity-ref> consideration of eligibility.</text>
          </subsection>
          <subsection id="id4b2216a501564acca58dd5ca05ec1699">
            <enum>(f)</enum>
            <header>New sunscreen
				condition application</header>
            <paragraph id="id8623E80F7C2D4B6385D455FEAFD1C27A">
              <enum>(1)</enum>
              <header>Eligibility
				determination</header>
              <text>Not later than 60 days after the submission of an eligibility
				application under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d" proposed="true">subsection (d)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall determine if
			 the sunscreen
				condition is eligible for further review for safety and
			 effectiveness. In the
				case of a sunscreen condition determined to be eligible, the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				publish a notice of eligibility in the Federal Register, and
			 provide interested persons an opportunity to submit published and
			 unpublished data related to the safety and effectiveness of the sunscreen
			 condition for its intended nonprescription uses, in accordance with
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:2" proposed="true">paragraph
			 (2)</cato:entity-ref>. In the
				case of a sunscreen condition determined not eligible, the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				issue a letter to the sponsor, which shall be made publicly
			 available.</text>
            </paragraph>
            <paragraph id="id69cdb37a1d0c4ea3ac8da22da3cd441a">
              <enum>(2)</enum>
              <header>Safety and
				effectiveness data submissions</header>
              <subparagraph id="id659349BE0F424806AD3D5D318DAD76A3">
                <enum>(A)</enum>
                <header>In
				general</header>
                <text>Within 60 days of the publication in the Federal Register
				of an application deemed eligible, as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:1" proposed="true">paragraph (1)</cato:entity-ref>,
			 the sponsor
				and other interested parties shall submit safety and effectiveness
			 data to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for further review, as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:2/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>.</text>
              </subparagraph>
              <subparagraph id="id7d5879909ed041cca05fc1653d5aa964">
                <enum>(B)</enum>
                <header>Required submissions regarding data</header>
                <text>Submissions under this
			 paragraph shall
				include the following:</text>
                <clause id="idF98A4640F19A47699CF6F15B71785E9E">
                  <enum>(i)</enum>
                  <header>Human safety data</header>
                  <subclause id="id2115070B46594576B5CC4F027D5B969A">
                    <enum>(I)</enum>
                    <header>Individual active components</header>
                    <text>With respect to individual active components, controlled studies, partially controlled or
			 uncontrolled studies,
			 documented case reports, pertinent marketing experiences that may
			 influence a determination as to the safety of each individual active
			 component, and pertinent medical and scientific literature.</text>
                  </subclause>
                  <subclause id="id15C06EBF47FB4D018BF0A6AF12F66642">
                    <enum>(II)</enum>
                    <header>Combinations of individual active components</header>
                    <text>With respect to combinations of the individual active components, controlled studies,
			 partially controlled or
			 uncontrolled studies, documented case reports, pertinent marketing
			 experiences that may influence a determination as to the safety of
			 combinations of the individual active component, and pertinent medical and
			 scientific literature.</text>
                  </subclause>
                </clause>
                <clause id="idF1EDE7393E72430BB5E0FA5EFA78D245">
                  <enum>(ii)</enum>
                  <header>Efficacy data</header>
                  <subclause id="idF6A6E648531D45F3ABFE3C6D47ABEBE4">
                    <enum>(I)</enum>
                    <header>Individual active components</header>
                    <text>With respect to individual active components, controlled studies, partially controlled or
			 uncontrolled
			 studies, documented case reports, pertinent marketing experiences that may
			 influence a determination on the efficacy of each individual active
			 component, pertinent medical and scientific literature.</text>
                  </subclause>
                  <subclause id="id9FB4AE5DDA3543E6AE5D73B220824838">
                    <enum>(II)</enum>
                    <header>Combinations of individual active components</header>
                    <text>With respect to combinations of the individual active components, controlled studies,
			 partially controlled or
			 uncontrolled studies, documented case reports, pertinent marketing
			 experiences that may influence a determination on the efficacy of
			 combinations of the individual active components, and pertinent medical
			 and scientific literature.</text>
                  </subclause>
                </clause>
                <clause id="idCB855D0C079241D89F236C1861C37B86">
                  <enum>(iii)</enum>
                  <header>Data setting forth medical rationale and purpose</header>
                  <text>A summary of the data and views setting forth the medical rationale and purpose (or lack thereof)
			 for the sunscreen condition and the scientific basis (or lack thereof) for
			 the conclusion that the condition has been proven safe and effective for
			 the intended use. If there is an absence of controlled studies in the
			 material submitted, an explanation as to why such studies are not
			 considered necessary must be included.</text>
                </clause>
                <clause id="id5698C72B269C4B028749E826EC33D0A7">
                  <enum>(iv)</enum>
                  <header>Official drug monograph</header>
                  <text>An applicable United States Pharmacopoeia or National Formulary for the
			 sunscreen active ingredient or a proposed standard for inclusion in an
			 article to be recognized in an official drug monograph for the
			 active ingredient, including information showing that the official or
			 proposed compendial monograph for the active ingredient is consistent with
			 the active ingredient used in the studies establishing safety and
			 effectiveness and with the active ingredient marketed in the
			 nonprescription product to a material extent and for a material time.
			 If differences exist between the official or proposed compendial
			 monograph for the active ingredient and the active ingredient that is the
			 subject of the application, sponsor shall explain such differences.</text>
                </clause>
                <clause id="idBF48A72D26B8448A9D650A19F7F97A95">
                  <enum>(v)</enum>
                  <header>Adverse drug experiences</header>
                  <text>A list of all serious adverse drug experiences, as defined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, from each country
			 where the
			 condition has been or is currently marketed as a prescription drug or as a
			 nonprescription drug or product.</text>
                </clause>
              </subparagraph>
              <subparagraph id="id8FC6E1BCF91A4C709A92BBED9A21BC42">
                <enum>(C)</enum>
                <header>Optional animal safety data</header>
                <text>In addition to the information required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:2/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>,  the sponsor may submit information
			 with respect to animal safety data, including controlled
			 studies and partially controlled or uncontrolled
			 studies, in the case of an application for individual active components,
			 and controlled
			 studies and partially controlled
			 or uncontrolled studies in the case of an application for combinations of
			 individual active components.</text>
              </subparagraph>
              <subparagraph commented="no" id="id996d652280954e01ab7879f683fdc713">
                <enum>(D)</enum>
                <header>Confidentiality
				of submissions</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make data and information
				submitted by the sponsor, or pursuant to a notice requesting safety
			 and
				effectiveness data published in the Federal Register, publicly
			 available, with
				redactions for confidential commercial information or trade secret
			 information,
				and any other information exempt from disclosure pursuant to
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18/1905">section 1905 of
				title 18, United States Code</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/552/b">
                    <external-xref legal-doc="usc" parsable-cite="usc/5/552">section 552(b)</external-xref> of title 5, United
			 States Code</cato:entity-ref>, or
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:j">section 301(j)</cato:entity-ref> of this Act.</text>
              </subparagraph>
            </paragraph>
            <paragraph id="idd2ac2ac6232a4248a1728e624d45e4be">
              <enum>(3)</enum>
              <header>New sunscreen
				condition application submission to the advisory committee</header>
              <text>Not
				later than 30 days after the end of the public comment period
			 described in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:2" proposed="true">paragraph (2)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall submit the application and the
			 safety and
				effectiveness data submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:2" proposed="true">paragraph (2)</cato:entity-ref> to the
			 Nonprescription Drugs
				Advisory Committee (referred to in this section as the <quote>advisory
				committee</quote>) for review.</text>
            </paragraph>
          </subsection>
          <subsection id="id196a47accc41461e9c07ae9cb2c876fe">
            <enum>(g)</enum>
            <header>Pending
				sunscreen condition applications</header>
            <text>Not later than 30 days after the
				date of enactment of the <short-title>
                <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sunscreen Innovation Act" proposed="true">Sunscreen Innovation
				Act</cato:entity-ref>
              </short-title>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall submit to the advisory committee all safety and effectiveness data submitted
			 with respect to each
				application for review of sunscreen conditions that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
			 had
				determined, prior to the date of enactment of the
				<short-title>
                <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sunscreen Innovation Act" proposed="true">Sunscreen Innovation Act</cato:entity-ref>
              </short-title>, to be
				eligible for review of safety and effectiveness and for which the
			 information
				required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:2" proposed="true">subsection (f)(2)</cato:entity-ref> has been submitted to the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> prior to
				such date of enactment.</text>
          </subsection>
          <subsection id="id113CBC59342646BC8B0BC3D20EA8968E">
            <enum>(h)</enum>
            <header>Review and
				recommendation for nonprescription sunscreen condition</header>
            <paragraph id="idB732E3D9AF8E448F8D3CC56EE5388CED">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall require the advisory committee to
				evaluate the safety and effectiveness data submitted in accordance
			 with
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:2" proposed="true">subsection (f)(2)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:g" proposed="true">(g)</cato:entity-ref>.</text>
            </paragraph>
            <paragraph id="id5B017840DE014C61B820B3DB25A3337A">
              <enum>(2)</enum>
              <header>Standards</header>
              <text>In
				evaluating a nonprescription sunscreen condition under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:1" proposed="true">paragraph
			 (1)</cato:entity-ref>, the
				advisory committee shall use the regulations in effect at the time
			 of the
				application, including regulations with respect to—</text>
              <subparagraph id="idF8DCEA34B759446EBD914CC6F34EC708">
                <enum>(A)</enum>
                <text>the safety of the
				nonprescription sunscreen condition;</text>
              </subparagraph>
              <subparagraph id="idF812C4339BE54A6297286BA928F8A1F0">
                <enum>(B)</enum>
                <text>the effectiveness
				of the nonprescription sunscreen condition;</text>
              </subparagraph>
              <subparagraph id="idA60006EEA1AB4818B5037652848165B1">
                <enum>(C)</enum>
                <text>the
				benefit-to-risk ratio of the nonprescription sunscreen condition;
			 and</text>
              </subparagraph>
              <subparagraph id="id8D3CB731E25846BDAEFC4122B9A5521E">
                <enum>(D)</enum>
                <text>the labeling of
				the nonprescription sunscreen condition.</text>
              </subparagraph>
            </paragraph>
            <paragraph id="idBBE44FC14BB1427A993EC669DD640F0A">
              <enum>(3)</enum>
              <header>Communications
				between advisory committee and other individuals who submit data</header>
              <text>The advisory committee
				shall have the authority to communicate with the sponsor and other
			 individuals who submit data during the
			 advisory
				committee's review, including requesting clarification or
			 additional
				information.</text>
            </paragraph>
            <paragraph id="id56E48445242D4AF7A28F54DF4BBBC12A">
              <enum>(4)</enum>
              <header>Recommendations</header>
              <subparagraph id="idF05AAC231780454F88429340C188D6E4">
                <enum>(A)</enum>
                <header>In
				general</header>
                <text>For each such submission under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:3" proposed="true">subsection (f)(3)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:g" proposed="true">(g)</cato:entity-ref>,
				the advisory committee shall make one of the following
			 recommendations to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>:</text>
                <clause id="idb7a18bcbf7874495bf31066414a75240">
                  <enum>(i)</enum>
                  <text>The sunscreen
				condition is generally recognized as safe and effective (including
			 any or all
				indications), including nonprescription sunscreen conditions for
			 which a new
				drug application has been approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
                </clause>
                <clause id="id7f22e8b5e10244f7b8b66392cf74afa3">
                  <enum>(ii)</enum>
                  <text>Insufficient
				information has been provided to support a
			 recommendation that
				the sunscreen condition is generally recognized as safe and
			 effective
				(including any or all indications).</text>
                </clause>
                <clause id="idad086b07ae32464d9d453a5fd52ed841">
                  <enum>(iii)</enum>
                  <text>The sunscreen
				condition is not generally recognized as safe and effective to be
			 marketed or sold, unless an
				application with respect to such condition is approved under
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">section
				505(b)</cato:entity-ref>.</text>
                </clause>
              </subparagraph>
              <subparagraph commented="no" id="id8a1c3b1b6ac04c5cb1c50701b20c7efa">
                <enum>(B)</enum>
                <header>Timing</header>
                <text>The
				advisory committee shall make a recommendation under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:4/sp:A" proposed="true">subparagraph
			 (A)</cato:entity-ref> not later
				than 180 days after the advisory committee receives the application
			 and data
				submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:3" proposed="true">subsection (f)(3)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:g" proposed="true">subsection (g)</cato:entity-ref>.</text>
              </subparagraph>
              <subparagraph commented="no" id="id3f9c00e70c6d40d58460ffedc1b1b510">
                <enum>(C)</enum>
                <header>Resubmission of
				data</header>
                <text>If the advisory committee recommends that insufficient
				information has been provided, in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:4/sp:A/cl:ii" proposed="true">subparagraph
			 (A)(ii)</cato:entity-ref>, the
				advisory committee shall make such recommendation not later than
			 180 days after
				the date on which such additional information is submitted.</text>
              </subparagraph>
            </paragraph>
          </subsection>
          <subsection id="idAF0EF215EF2C4C709C82DE57F4ED852A">
            <enum>(i)</enum>
            <header>Determination
				by the Center for Drug Evaluation and Research</header>
            <paragraph id="id9691662fef1a478b8791cceb94bda2b6">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug Evaluation and Research</cato:entity-ref> shall respond
				to the recommendations of the advisory committee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:4" proposed="true">subsection
			 (h)(4)</cato:entity-ref> as
				follows:</text>
              <subparagraph id="iddc61ea94ccd64b5e9867ec3152b3bf2c">
                <enum>(A)</enum>
                <text>In the case of a
				recommendation by the advisory committee described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:4/sp:A/cl:i" proposed="true">clause (i) of
				subsection (h)(4)</cato:entity-ref>, not later than 45 days after the advisory
			 committee issues
				the recommendation, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug Evaluation and Research</cato:entity-ref>
			 shall issue a
				determination affirming or denying the recommendation of the
			 advisory
				committee. If the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug Evaluation and Research</cato:entity-ref> affirms
			 the
				recommendation of the advisory committee, or if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug
			 Evaluation
				and Research</cato:entity-ref> takes no action regarding the recommendation within 45
			 days of
				receiving such recommendation, the nonprescription sunscreen
			 condition shall be
				generally recognized as safe and effective, not misbranded, and
			 permitted to be
				marketed and sold in accordance with all applicable rules and
			 regulations for
				over-the-counter drugs.</text>
              </subparagraph>
              <subparagraph id="id7f42b8df85554204bec490178e3ea21f">
                <enum>(B)</enum>
                <text>In the case of a
				recommendation described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:4/sp:A/cl:ii" proposed="true">clause (ii)</cato:entity-ref> of such subsection, the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug
				Evaluation and Research</cato:entity-ref> shall issue a determination affirming or
			 denying the recommendation of the advisory committee, to be made publicly
			 available,
				within 45 days of receiving the recommendation, and inform the
			 sponsor that the sponsor must submit additional
			 information to the advisory committee in order to continue the
				review by the advisory committee.</text>
              </subparagraph>
              <subparagraph id="idae4ce6d59928428992d6685027a210d2">
                <enum>(C)</enum>
                <text>In the case of a
				recommendation described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:4/sp:A/cl:iii" proposed="true">clause (iii)</cato:entity-ref> of such subsection, the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for
				Drug Evaluation and Research</cato:entity-ref> shall issue a determination affirming
			 or denying the recommendation of the advisory committee, to be made
			 publicly
				available, within 45 days of receiving such recommendation,
			 and indicate whether
				such sunscreen condition determined to be not generally recognized
			 as safe and
			 effective to
				be marketed and sold, unless an application with respect to such
				condition is approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">section 505(b)</cato:entity-ref>, or whether additional
			 data must be submitted to the advisory committee.</text>
              </subparagraph>
            </paragraph>
            <paragraph id="id597C0054D6E04C51A039F6715AC8D812">
              <enum>(2)</enum>
              <header>Supervisory
				review of determination</header>
              <subparagraph id="idCE29932071AA47C096FBE3B87A225110">
                <enum>(A)</enum>
                <header>In
				general</header>
                <text>Any person may request a supervisory review of a
				determination of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug Evaluation and Research</cato:entity-ref> to not
			 accept a recommendation of an advisory committee. Such review may be
			 conducted at the next
			 supervisory
				or higher level above the individual who made the determination.</text>
              </subparagraph>
              <subparagraph id="id78d8367837644f9db9ead57efe4e62e0">
                <enum>(B)</enum>
                <header>Request for
				supervisory review</header>
                <text>A request described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:i/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall
				be made to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> not later than 30 days after such decision
			 and shall
				indicate in the request whether such person seeks an in-person
			 meeting or a
				teleconference. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall schedule an in-person or
			 teleconference
				review, if so requested, not later than 30 days after such request
			 is made. The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue a decision to the person requesting a review
			 under this
				paragraph not later than 45 days after the meeting.</text>
              </subparagraph>
              <subparagraph id="idaf69e62cfb6645c0b9a7e8ec07e5211e">
                <enum>(C)</enum>
                <header>Standard of
				supervisory review</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall be authorized to overturn
				a determination of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug Evaluation and Research</cato:entity-ref> not
			 to accept a
				recommendation of the advisory committee if the
			 supervisory review
				results in a decision by the reviewer that the individual who made
			 the
				determination did not provide reasonable and sufficient substantive
			 support for
				the decision to disregard the advisory committee's
				recommendation.</text>
              </subparagraph>
              <subparagraph commented="no" id="idfd637d9fc85642f59ba067d16a52d514">
                <enum>(D)</enum>
                <header>Supervisory
				review decision</header>
                <text>If the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> overturns a determination by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug Evaluation and Research</cato:entity-ref> not to accept a favorable
				recommendation of an advisory committee, the nonprescription
			 sunscreen
				condition shall be generally recognized as safe and effective, not
			 misbranded,
				and permitted to be marketed and sold in accordance with all
			 applicable rules
				and regulations for over-the-counter drugs.</text>
              </subparagraph>
              <subparagraph commented="no" id="id9A846FDE48AF41B4B70112B7C176FEAD">
                <enum>(E)</enum>
                <header>Final agency
				action</header>
                <text>A decision made through supervisory review shall
				constitute final agency action subject to judicial review.</text>
              </subparagraph>
            </paragraph>
          </subsection>
          <subsection id="id58CA10D2CB3B416F974CAFA3195761C2">
            <enum>(j)</enum>
            <header>Reports</header>
            <paragraph id="id4A5099986A7F4F5E881C93BA5A8D2FB3">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>Not later than 1 year after the date of enactment of the
				<short-title>
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sunscreen Innovation Act" proposed="true">Sunscreen Innovation Act</cato:entity-ref>
                </short-title>, on
				March 1, 2015, and every 2 years thereafter, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
			 issue a report
				to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> describing actions taken under this section.</text>
            </paragraph>
            <paragraph id="id021FCE2407114618B8178007EA14F315">
              <enum>(2)</enum>
              <header>Contents</header>
              <text>The
				reports under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:j/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall include—</text>
              <subparagraph id="id92A84768472B4088B110296ACA097D95">
                <enum>(A)</enum>
                <text>a review of the
				progress made in issuing in a timely manner decisions on the safety
			 and
				effectiveness for sunscreen conditions for applications pending as
			 of the date
				of enactment of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sunscreen Innovation Act" proposed="true">Sunscreen Innovation
				Act</cato:entity-ref>
                  </short-title>, including the number of pending applications—</text>
                <clause id="id0C47EFF713D84ED29765B07CA5BA395B">
                  <enum>(i)</enum>
                  <text>reviewed and the
				decision times for each application, measured from the date of
			 original
				eligibility application submission by the sponsor;</text>
                </clause>
                <clause id="id608C7859176C4E129ED073F7E032B16E">
                  <enum>(ii)</enum>
                  <text>resulting in a
				determination of generally recognized as safe and effective and not
				misbranded;</text>
                </clause>
                <clause id="idE11AF46967FC40A4A76E8F26D9DA6490">
                  <enum>(iii)</enum>
                  <text>resulting in a
				determination of not generally recognized as safe and effective and
			 not
				misbranded and the reasons for such determinations; and</text>
                </clause>
                <clause id="id7E61E490F2D64E518CBDF2A8D5EDE1B4">
                  <enum>(iv)</enum>
                  <text>for which a
				determination has not been made, an explanation for the delay, a
			 description of
				the current status of each such application, and the length of time
			 such
				applications have been pending, measured from the date of original
			 eligibility
				application submission by the sponsor;</text>
                </clause>
              </subparagraph>
              <subparagraph id="idFA27F71040FF44FB8576886B862A6D47">
                <enum>(B)</enum>
                <text>a review of the
				progress made in issuing in a timely manner a decision on safety
			 and
				effectiveness for sunscreen condition applications submitted after
			 the date of
				enactment of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sunscreen Innovation Act" proposed="true">Sunscreen Innovation
				Act</cato:entity-ref>
                  </short-title>, including the number of such applications—</text>
                <clause id="idC3A9A27BC19E4FE28316D081447EE68E">
                  <enum>(i)</enum>
                  <text>reviewed and the
				decision times for each application;</text>
                </clause>
                <clause id="idAC747645164848B9A09BAEC779C183A9">
                  <enum>(ii)</enum>
                  <text>resulting in a
				determination of generally recognized as safe and effective and not
			 misbranded;
				and</text>
                </clause>
                <clause id="idE4B16F304D18405D923AB993AC5F6CF8">
                  <enum>(iii)</enum>
                  <text>resulting in a
				determination of not generally recognized as safe and effective and
			 not
				misbranded and the reasons for such determinations;</text>
                </clause>
              </subparagraph>
              <subparagraph id="idCC91246580CF441389C09C0FE65DAAC3">
                <enum>(C)</enum>
                <text>a description of
				the staffing and resources relating to the costs associated with
			 the review and
				decisionmaking pertaining to applications;</text>
              </subparagraph>
              <subparagraph id="id4c31d2d3eb964d59b3c02b28c35baeb0">
                <enum>(D)</enum>
                <text>a review of the
				progress in meeting the deadlines with respect to processing
			 applications under
				this section;</text>
              </subparagraph>
              <subparagraph id="id4c0754c503a246e381709ed87ef6555b">
                <enum>(E)</enum>
                <text>to the extent the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines appropriate, recommendations for process
			 improvements in
				the handling of pending and new applications; and</text>
              </subparagraph>
              <subparagraph id="idDB4EDC065DDC49F7B0EEDCB527861522">
                <enum>(F)</enum>
                <text>recommendations
				for expanding the applicability of this section to nonprescription
			 active
				ingredients or conditions that are not related to the sunscreen
			 category of
				over-the-counter drugs.</text>
              </subparagraph>
            </paragraph>
            <paragraph id="id44340A0E006A4C63936298CB9C55AE51">
              <enum>(3)</enum>
              <header>Method</header>
              <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall publish the reports required under this subsection
			 in the
				manner the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines to be the most effective for
			 efficiently
				disseminating the report, including publication of the report on
			 the Internet
				website of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>.</text>
            </paragraph>
          </subsection>
          <subsection id="idD9FB621EE1AA417599CC41A5CB5E0927">
            <enum>(k)</enum>
            <header>Rules of
				construction</header>
            <paragraph id="id93375E09D5CC42B6B0C661AAC4F26B07">
              <enum>(1)</enum>
              <header>Authority to
				withdraw or suspend</header>
              <text>Nothing in this section shall be construed to
				alter the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary's</cato:entity-ref> authority to withdraw or suspend from the
			 market
			 a drug that
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines to be unsafe or ineffective.</text>
            </paragraph>
            <paragraph id="idCAF8FD8BD7CB49C69C69735F478D4C56">
              <enum>(2)</enum>
              <header>Other
				conditions</header>
              <text>Nothing in the section shall affect the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary's</cato:entity-ref>
				authority to review nonprescription conditions other than sunscreen
				conditions.</text>
            </paragraph>
          </subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
    </section>
    <section id="id9B8BABF0397C43BBBAA5979D7B0E6A04">
      <enum>3.</enum>
      <header>Sunscreen
			 testing and labeling</header>
      <text display-inline="no-display-inline">Not later
			 than 180 days after the date of enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
			 issue determinations with respect to—</text>
      <paragraph id="idCF236921E93F418481C0E0ED8BDCCF9A">
        <enum>(1)</enum>
        <text display-inline="yes-display-inline">the appropriate testing and labeling
			 requirements for sunscreens sold as an aerosol; and</text>
      </paragraph>
      <paragraph id="id914B7DEC59664ADB9EB94BCC5DAC6C35">
        <enum>(2)</enum>
        <text display-inline="yes-display-inline">whether sunscreen may contain a label
			 indicating a sun protection factor greater than 50.</text>
      </paragraph>
    </section>
  </legis-body>
</bill>
</doc>